Natco Pharma Submits ANDA to FDA for Generic Breast Cancer Drug

by Kathy Jones on  June 24, 2011 at 6:31 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

Natco Pharma announced that it has submitted an abbreviated new drug application (ANDA) to the US Food and Drug Administration for the sale of its generic breast cancer drug, Lapatinib Ditosylate tablets which is will be manufacturing in partnership with Lupin Ltd.
 Natco Pharma Submits ANDA to FDA for Generic Breast Cancer Drug
Natco Pharma Submits ANDA to FDA for Generic Breast Cancer Drug

Announcing the partnership in a press statement, Lupin said that the Lapatinib Ditosylate tablets, which are sold under the brand name of Tykerb in the US, had annual sales of over $113 million last year.

"Tykerb had sales of $113.6 million as of March, 2011, according to IMS health. Natco and Lupin believe that they are the first to file an ANDA containing a paragraph IV certification for Lapatinib", the company said.

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Women and Cancer Drug Toxicity Breast Biopsy Pagets disease of the breast Mastitis Cancer and Homeopathy Signature Drug Toxicity Breast Cancer Facts Cancer Facts Cancer 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive